<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d254" origId="Nilutamide"><sentence id="DrugDDI.d254.s0" origId="s0" text="In vitro, nilutamide has been shown to inhibit the activity of liver cytochrome P-450 isoenzymes and therefore, may reduce the metabolism of compounds requiring these systems."><entity id="DrugDDI.d254.s0.e0" origId="s0.p0" charOffset="10-20" type="drug" text="nilutamide"/><entity id="DrugDDI.d254.s0.e1" origId="s0.p7" charOffset="69-85" type="drug" text="cytochrome P-450"/><pair id="DrugDDI.d254.s0.p0" e1="DrugDDI.d254.s0.e0" e2="DrugDDI.d254.s0.e1" interaction="true"/></sentence><sentence id="DrugDDI.d254.s1" origId="s1" text="Consequently, drugs with a low therapeutic margin, such as vitamin K antagonists, phenytoin, and theophylline, could have a delayed elimination and increases in their serum half-life leading to a toxic level."><entity id="DrugDDI.d254.s1.e0" origId="s1.p17" charOffset="14-19" type="drug" text="drugs"/><entity id="DrugDDI.d254.s1.e1" origId="s1.p20" charOffset="82-91" type="drug" text="phenytoin"/><entity id="DrugDDI.d254.s1.e2" origId="s1.p22" charOffset="97-109" type="drug" text="theophylline"/><pair id="DrugDDI.d254.s1.p0" e1="DrugDDI.d254.s1.e0" e2="DrugDDI.d254.s1.e1" interaction="false"/><pair id="DrugDDI.d254.s1.p1" e1="DrugDDI.d254.s1.e0" e2="DrugDDI.d254.s1.e2" interaction="false"/><pair id="DrugDDI.d254.s1.p2" e1="DrugDDI.d254.s1.e1" e2="DrugDDI.d254.s1.e2" interaction="false"/></sentence><sentence id="DrugDDI.d254.s2" origId="s2" text="The dosage of these drugs or others with a similar metabolism may need to be modified if they are administered concomitantly with nilutamide."><entity id="DrugDDI.d254.s2.e0" origId="s2.p31" charOffset="20-25" type="drug" text="drugs"/><entity id="DrugDDI.d254.s2.e1" origId="s2.p44" charOffset="130-140" type="drug" text="nilutamide"/><pair id="DrugDDI.d254.s2.p0" e1="DrugDDI.d254.s2.e0" e2="DrugDDI.d254.s2.e1" interaction="true"/></sentence><sentence id="DrugDDI.d254.s3" origId="s3" text="For example, when vitamin K antagonists are administered concomitantly with nilutamide, prothrombin time should be carefully monitored and if necessary, the dosage of vitamin K antagonists should be reduced."><entity id="DrugDDI.d254.s3.e0" origId="s3.p51" charOffset="76-86" type="drug" text="nilutamide"/></sentence></document>